Analyst Price Targets — PCRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 8, 2025 9:27 pm | — | Barclays | $27.00 | $24.42 | TheFly | Pacira initiated with an Equal Weight at Barclays |
| February 28, 2025 6:37 pm | — | Barclays | $24.00 | $24.05 | TheFly | Pacira price target raised to $24 from $17 at Barclays |
| February 28, 2025 11:11 am | — | H.C. Wainwright | $48.00 | $24.05 | TheFly | Pacira price target raised to $48 from $39 at H.C. Wainwright |
| January 30, 2025 11:03 am | Les Sulewski | Truist Financial | $25.00 | $26.03 | StreetInsider | Truist Securities Upgrades Pacira Pharmaceuticals (PCRX) to Buy |
| November 7, 2024 12:42 pm | David Amsellem | Piper Sandler | $12.00 | $17.37 | StreetInsider | Pacira Pharmaceuticals (PCRX) PT Raised to $12 at Piper Sandler |
| September 24, 2024 9:32 am | Glen Santangelo | Jefferies | $18.00 | $14.77 | StreetInsider | Pacira Pharmaceuticals (PCRX) PT Raised to $18 at Jefferies |
| August 13, 2024 6:08 am | Les Sulewski | Truist Financial | $8.00 | $12.29 | TheFly | Pacira downgraded to Sell from Buy at Truist |
| July 2, 2024 12:36 pm | Oren Livnat | H.C. Wainwright | $57.00 | $21.91 | TheFly | Pacira should be bought on today's selloff, says H.C. Wainwright |
| June 13, 2024 11:57 am | Glen Santangelo | Jefferies | $36.00 | $28.50 | StreetInsider | Jefferies Reiterates Buy Rating on Pacira Pharmaceuticals (PCRX) |
| May 21, 2024 8:52 am | David Amsellem | Piper Sandler | $42.00 | $30.68 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Pacira Pharmaceuticals (PCRX) |
Latest News for PCRX
BRISBANE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its first quarter 2026 financial results after the close of the U.S. markets on Thursday April 30, 2026.
-- Select findings demonstrate that the use of EXPAREL ® (bupivacaine liposome injectable suspension) in outpatient Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) is associated with lower total healthcare costs over various follow-up periods —
BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the 25th Annual Needham Virtual Healthcare Conference at 9:30 AM ET on Wednesday, April 15, 2026.
-- Studies highlight reduced total cost of care and select healthcare resource utilization outcomes in total knee arthroplasty (TKA) and spinal fusion -- BRISBANE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced findings from two real-world…
Shares of Pacira BioSciences, Inc. (NASDAQ: PCRX - Get Free Report) have been assigned an average rating of "Hold" from the six research firms that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PCRX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.